Welcome to our dedicated page for Madrigal Pharmac news (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmac stock.
Madrigal Pharmaceuticals, Inc. (MDGL) is a clinical-stage biopharmaceutical company pioneering treatments for metabolic dysfunction-associated steatohepatitis (MASH), including its FDA-approved therapy Rezdiffra. This page provides investors and healthcare professionals with timely updates on corporate milestones, clinical research, and regulatory developments.
Access the latest press releases, earnings reports, and scientific announcements in one centralized location. Key updates include Rezdiffra's commercialization progress, new clinical data analyses, and strategic partnerships advancing MASH treatment innovation. Our curated news collection ensures you stay informed about material events without speculative commentary.
Regular updates cover regulatory submissions, trial expansions, financial disclosures, and patient access initiatives. Content is rigorously verified to provide accurate, actionable information for investment and therapeutic decision-making. Bookmark this page to monitor Madrigal's progress in addressing critical unmet needs in liver disease therapeutics.
Madrigal Pharmaceuticals (NASDAQ: MDGL), a biopharmaceutical company specializing in novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), has scheduled its first-quarter 2025 financial results release for Thursday, May 1, 2025, before U.S. markets open.
The company will host a live webcast at 8 a.m. Eastern Time where management will review financial and operating results. Participants are advised to register 15 minutes before the scheduled webcast, which will be accessible through the Investor Relations section of Madrigal's website. A replay will be available approximately two hours after the live event.
Madrigal Pharmaceuticals (NASDAQ: MDGL) announced key leadership changes as company founder Rebecca Taub, M.D., transitions from Chief Medical Officer and President of R&D to Senior Scientific and Medical Advisor, while maintaining her position on the Board of Directors. David Soergel, M.D., has been appointed as the new Executive Vice President and Chief Medical Officer, effective April 21, 2025.
Dr. Taub's legacy includes pioneering the development of Rezdiffra™ (resmetirom), the first FDA-approved medicine for treating metabolic dysfunction-associated steatohepatitis (MASH). Under her leadership, Madrigal grew from a small R&D team of fewer than 10 professionals to a commercial-stage biopharma company with over 500 employees across the U.S. and Europe.
Dr. Soergel joins from Novartis, where he served as Executive Vice President and Global Head of Cardiovascular, Renal, and Metabolism Development, overseeing 10 late-stage development programs in 2024. The company currently has two fully enrolled outcomes studies of Rezdiffra underway.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has appointed Jacqualyn "Jackie" Fouse, Ph.D. to its Board of Directors, while Fred Craves, Ph.D. will retire from the Board in July 2025. Fouse brings over 30 years of healthcare industry and finance experience, having previously served as CEO of Agios Pharmaceuticals and held executive positions at Celgene , Bunge , and Alcon Laboratories.
The appointment aligns with Madrigal's strategic focus on metabolic dysfunction-associated steatohepatitis (MASH). The company aims to drive the launch of Rezdiffra, their first approved MASH treatment, expand geographically, advance their clinical program in compensated MASH cirrhosis, and build their pipeline.
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported strong Q4 and full-year 2024 results for Rezdiffra™, the first FDA-approved MASH treatment. Q4 net sales reached $103.3 million, contributing to full-year sales of $180.1 million. The company ended 2024 with $931.3 million in cash and equivalents.
New two-year data from the Phase 3 MAESTRO-NAFLD-1 trial showed promising results for patients with compensated MASH cirrhosis, including a mean 6.7 kPa reduction in liver stiffness, with 51% of patients achieving ≥25% reduction. These results support Rezdiffra's potential benefit in cirrhosis patients.
Key 2024 milestones included FDA approval in March, commercial launch in April, and recognition in updated EASL and AASLD guidelines as first-line therapy. The company completed enrollment in the MAESTRO-NASH OUTCOMES trial, with data expected in 2027. European expansion is planned for H2 2025, pending EMA approval.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra™ (resmetirom). The study showed significant improvements in liver health markers:
- Patients achieved a mean 6.7 kPa reduction in liver stiffness after two years of treatment
- 51% of patients achieved ≥25% reduction in liver stiffness
- Mean liver stiffness at baseline was 25 kPa
The safety and tolerability profile remained consistent with previous trials, showing low discontinuation rates due to adverse events. While Rezdiffra is currently approved for treating adults with noncirrhotic MASH with F2 to F3 fibrosis, it is not yet approved for MASH cirrhosis patients. The company's ongoing MAESTRO-NASH OUTCOMES trial aims to establish safety and efficacy for cirrhosis treatment.
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced its participation in the upcoming 45th Annual TD Cowen Health Care Conference. The company's presentation is scheduled for Tuesday, March 4, 2025, at 11:10 A.M. ET.
The event will feature a live webcast accessible through a direct link or via Madrigal's Investor Relations Events page. For those unable to attend the live presentation, a replay option will be made available following the event.
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced it will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 26, 2025, before U.S. markets open. The company's management will host a live webcast at 8 a.m. Eastern Time to discuss financial and operating results.
Participants can access the webcast through the Investor Relations section of Madrigal's website and are advised to register 15 minutes before the scheduled start. A replay will be available approximately two hours after the live event.
Madrigal Pharmaceuticals (NASDAQ:MDGL) has announced strong preliminary results for Q4 and full-year 2024. The company reported Q4 Rezdiffra net sales between $100-103 million and full-year sales of $177-180 million. As of year-end 2024, the company maintains a robust cash position of approximately $931 million and has more than 11,800 patients on Rezdiffra.
2024 marked a pivotal year for Madrigal with several key achievements: Rezdiffra received FDA approval in March as the first and only approved treatment for MASH (metabolic dysfunction-associated steatohepatitis), the EMA validated their Marketing Authorization Application, and enrollment was completed in the MAESTRO-NASH OUTCOMES study for compensated cirrhosis patients. The company plans European expansion starting with Germany in H2 2025, pending EMA approval expected mid-2025.
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's presentation is scheduled for Wednesday, January 15, 2025, at 2:15 pm PT. Interested parties can access the live webcast through either a direct link or via the Events and Presentations section of Madrigal's Investor Relations website.
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced its participation in three major investor conferences. The company will engage in fireside chats at the UBS Global Healthcare Conference on November 13, 2024 at 2:00 PM EST, the 7th Annual Evercore HealthCONx Conference on December 4, 2024 at 9:35 AM EST, and the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 8:30 AM EST. All presentations will be available via live webcast through Madrigal's Investor Relations Events page.
